Publicaciones en colaboración con investigadores/as de University College London (50)

2024

  1. Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe

    Pediatric Infectious Disease Journal, Vol. 43, Núm. 5, pp. E155-E159

2023

  1. Hepatitis delta infection among persons living with HIV in Europe

    Liver International, Vol. 43, Núm. 4, pp. 819-828

2022

  1. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

    HIV Medicine, Vol. 23, Núm. 6, pp. 684-692

  2. Observational cohort study of rilpivirine (RPV) utilization in Europe

    AIDS Research and Therapy, Vol. 19, Núm. 1

  3. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

    HIV Medicine, Vol. 23, Núm. 6, pp. 585-598

  4. The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: Regional and intra-regional differences

    AIDS, Vol. 36, Núm. 3, pp. 423-435

2021

  1. CD4+:CD8+ T-cell ratio changes in people with HIV receiving antiretroviral treatment

    Antiviral Therapy, Vol. 25, Núm. 2, pp. 91-100

  2. Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality—a multicentre prospective cohort study

    BMC Infectious Diseases, Vol. 21, Núm. 1

  3. Healthcare delivery for HIV-positive people with tuberculosis in Europe

    HIV Medicine, Vol. 22, Núm. 4, pp. 283-293

  4. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

    Journal of Acquired Immune Deficiency Syndromes, Vol. 87, Núm. 2, pp. 806-817

  5. Prevalence and outcomes of pregnancies in women with HIV over a 20-year period

    AIDS (London, England), Vol. 35, Núm. 12, pp. 2025-2033

  6. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

    Annals of Internal Medicine, Vol. 174, Núm. 6, pp. 768-776

2020

  1. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: A sub-study of the NEAT001/ANRS143 randomized trial

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 3, pp. 628-639

2019

  1. Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals with Sustained Virological Suppression on Antiretroviral Therapy

    Journal of Acquired Immune Deficiency Syndromes, Vol. 80, Núm. 3, pp. 292-300

  2. Effectiveness of Transmitted Drug Resistance Testing before Initiation of Antiretroviral Therapy in HIV-Positive Individuals

    Journal of Acquired Immune Deficiency Syndromes, Vol. 82, Núm. 3, pp. 314-320

  3. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

    HIV Medicine, Vol. 20, Núm. 4, pp. 264-273

  4. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

    AIDS, Vol. 33, Núm. 13, pp. 2013-2024

2018

  1. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

    HIV Medicine, Vol. 19, Núm. 4, pp. 252-260

  2. Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance

    AIDS, Vol. 32, Núm. 3, pp. 327-335

  3. HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay

    HIV Medicine, Vol. 19, Núm. 1, pp. 33-41